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Microfluidic Cell Retention Device 
for Perfusion of Mammalian 
Suspension Culture
Taehong Kwon1, Holly Prentice2, Jonas De Oliveira3, Nyasha Madziva3, Majid Ebrahimi 
Warkiani  4, Jean-François P. Hamel3 & Jongyoon Han1,5,6
Continuous production of biologics, a growing trend in the biopharmaceutical industry, requires a 
reliable and efficient cell retention device that also maintains cell viability. Current filtration methods, 
such as tangential flow filtration using hollow-fiber membranes, suffer from membrane fouling, leading 
to significant reliability and productivity issues such as low cell viability, product retention, and an 
increased contamination risk associated with filter replacement. We introduce a novel cell retention 
device based on inertial sorting for perfusion culture of suspended mammalian cells. The device was 
characterized in terms of cell retention capacity, biocompatibility, scalability, and long-term reliability. 
This technology was demonstrated using a high concentration (>20 million cells/mL) perfusion culture 
of an IgG1-producing Chinese hamster ovary (CHO) cell line for 18–25 days. The device demonstrated 
reliable and clog-free cell retention, high IgG1 recovery (>99%) and cell viability (>97%). Lab-scale 
perfusion cultures (350 mL) were used to demonstrate the technology, which can be scaled-out with 
parallel devices to enable larger scale operation. The new cell retention device is thus ideal for rapid 
perfusion process development in a biomanufacturing workflow.
In the biopharmaceutical industry, continuous bioprocessing is widely recognized as a next generation biomanu-
facturing platform for reducing manufacturing cost and improving product quality1, 2. Perfusion process is used 
in bioproduction to achieve high cell concentration (up to 100 million cells/mL) in bioreactors and to enhance 
volumetric productivity, compared with fed-batch process3. In perfusion culture mode, fresh medium is continu-
ously perfused into the bioreactor, and growth-inhibiting metabolites and recombinant products are concurrently 
removed from the bioreactor using a cell retention device to maintain cells in the bioreactor.
Recent studies have reviewed cell retention devices for the perfusion culture of suspended mammalian 
cells, including membrane filtration, gravitational settling, centrifugation, and acoustic wave separation3–8. 
The hollow-fiber membrane filter is often used in industry and academia either in the Tangential (cross) Flow 
Filtration (TFF) or the Alternating Tangential-flow Filtration (ATF) configurations3–13. In both systems, a filter 
module of hollow fibers is externally placed next to a bioreactor, and a pump feeds the cell culture in the bioreac-
tor to the filter module. In TFF, the feed stream flows tangentially on the surface of the hollow-fiber membrane 
and generates permeate and retentate streams. The permeate stream contains the solute and particles which can 
move through the pores of the hollow-fiber membrane. The retentate carries the molecules and particles that are 
too large to pass through the pores.
The hollow-fiber membranes used in the perfusion process, however, are prone to foul due to pore blockage 
and cake formation by cells and molecules14. To reduce membrane fouling and increase the filter lifetime, ATF 
technology uses a diaphragm to generate rapid and repeated flow cycles between a bioreactor and a membrane 
module4, 6, 8–11, 15. However, ATF remains susceptible to membrane fouling8, 10, 16, 17. The fouling becomes more 
severe as the cell concentration, permeate flow rate, and cultivation time increase, and the viability decreases10. 
Furthermore, high-molecular-weight products generated from cells, such as antibodies and enzymes, may be 
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retained behind the hollow-fiber membrane filter in TFF and ATF7, 8, 11, 13, 18, 19 due to membrane fouling and con-
centration polarization14, 20. This potentially diminishes protein recovery and increases the protein residence time 
in the bioreactor. Also, unwanted smaller dead cells and cell debris produced during cultivation21 are retained 
by the hollow-fiber membrane filter and may release proteolytic enzymes in the bioreactor, possibly affecting 
productivity22 and product quality23.
Microfluidic methods for hydrodynamically sorting or separating cells at high-throughput (on the order of a 
few mL/min per single microchannel) have recently been developed24. Inertial microfluidics25–27, one of the most 
successful methods for high-throughput cell sorting27, utilizes a combination of hydrodynamic forces dependent 
on particle size in order to focus and separate particles laterally in a continuous flow within the channel. The 
control of the motion of particles only requires hydrodynamic forces that are derived from channel structure and 
particles, without the need for active force fields, such as electric fields or acoustic waves. As such, the inertial 
microfluidics enables fast, simple and cost-effective cell sorting and separation. Inertial migration in microfluidic 
channels has previously been applied for the separation of microparticles28, isolation of circulating tumor cells29, 30, 
detection of malaria pathogen31, and synchronization of cell cycle32, 33. Scale-out through parallelization of devices 
can easily increase the overall flow throughput further (up to 1 L/min)33–35. Sensitive cells such as mesenchymal 
stem cells and leukocytes have been tested in the spiral microchannels demonstrating that this processing does 
not affect indicators of cell viability, such as membrane permeability and surface proteins36, 37. Moreover, it was 
shown that spiral cell sorting does not induce up-regulation of a shear stress-related gene of the CHO cells33.
In this paper, we demonstrate a novel membrane-less cell retention device based on inertial sorting for continu-
ous perfusion culture of suspended mammalian cells. The spiral microchannel with trapezoidal cross-section 30, 36, 38  
is the basis for a membrane-less cell retention device for perfusion of mammalian cell suspension cultures in this 
work. We characterized the key performance index of the cell retention device for long-term perfusion culture, 
in terms of cell retention efficiency, biocompatibility, and scalability. Proof-of-concept perfusion cultures of sus-
pended IgG1-producing CHO cells at a concentration of 20–30 million cells/mL were performed over 18–25 days. 
The comparison of IgG1 concentrations between the bioreactor and harvest samples showed that the product 
recovery efficiency was high (>99%) during the perfusion culture. As an example of a microfluidic cell separation 
device compatible with large-volume continuous processing systems, the presented work shows a possibility to 
expand the range and impact of microfluidics applications beyond small-volume diagnostic use.
Results
Working principle and design of the microfluidic cell retention device. Neutrally-buoyant particles 
or cells suspended in a liquid flowing in a straight channel experience a net lift force (FL), which is a combination 
of shear gradient-induced and wall-induced lift forces25–27. The curved channels such as spirals generate two 
counter-rotating flows called Dean vortices perpendicular to the direction of the main flow, inducing an addi-
tional drag force (FD) on particles or cells25–27. Both FL and FD are size-dependent (FL ∝ a4 and FD ∝ a, where a is 
the particle diameter)27, and the combination of these forces laterally shifts particles/cells toward a single equilib-
rium position along the channel.
The membrane in ATF and TFF systems retains cells and enables the removal of cell-free by-products (Fig. 1a). 
Inertial sorting eliminates the need for this membrane, in that cells are sorted away from the junction by only 
hydrodynamic forces (Fig. 1a).
The spiral microfluidic cell retention device used in this work has one inlet and two outlets (Fig. 1b). The CHO 
cells of diameter 17.7 μm ± 2.5 μm (mean ± s.d., n = 19,346) (Supplementary Fig. S1 and Supplementary Table S1) 
are initially randomly dispersed in the channel and then begin to occupy their equilibrium position near the 
inner wall of the channel (Fig. 1b). In this way, the cells are retained through the inner outlet of the channel, and 
cell-limited harvest is collected through the outer outlet of the channel (Fig. 1b and Supplementary Video S1). 
When CHO cell culture at the input cell concentration of 10.5 million cells/mL was flowing into the single micro-
fluidic device at the flow rate of 1 mL/min, the collected solution from the outer outlet of the channel was visually 
clear (0.3 million cells/mL) compared to the solution (12.7 million cells/mL) from the inner outlet (Fig. 1b). This 
demonstrated the membrane-less cell-solution separation capability of the device.
Cell retention device characterization. The cell retention device was characterized in terms of cell reten-
tion efficiency, biocompatibility, and scalability.
Retention of the cells in a bioreactor through a cell retention device is required to reach and maintain a high 
productivity. Since the focusing behavior of the CHO cells in the microfluidic cell retention device depends on 
device dimension, cell culture flow rate, and cell concentration, the optimal operation conditions for high cell 
retention during perfusion cultures need to be studied. Here we define the cell retention efficiency R as 




, where XI is the cell concentration in the bioreactor and XOO is the cell concentration in 
the harvest stream. Lower cell concentration in the outer outlet of the device yields higher cell retention 
efficiency.
Given a fixed channel dimension (600 μm width, 80 μm inner depth, and 130 μm outer depth), the cell reten-
tion efficiency depends on input flow rate, fluidic resistance ratio at the outlets, and input cell concentrations 
(Fig. 2a–c). The CHO cells were focused near the inner wall of the channel at the flow rate of <1.5 mL/min, and 
this resulted in high cell retention efficiencies of 99.6% ± 0.3% (mean ± s.d., n = 9) at the input concentration of 
4.8 million cells/mL (Fig. 2a). As the flow rate increased, the smaller CHO cells (<10 μm) started to shift their 
equilibrium positions near the outer wall of the channel, leading to loss of these smaller cells into the outer outlet 
of the device and reduced cell retention efficiencies of 85% (3%) and 46% (6%) (mean (range), n = 3) at the flow 
rates of 2.2 and 2.6 mL/min, respectively (Fig. 2a).
The fluidic resistance ratio at the outlets also affected the cell retention efficiency by modulating the stream-
line boundary between two flows for the inner outlet and outer outlet at the channel bifurcation (Fig. 2b and 
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Supplementary Fig. S2). The higher fluidic resistance for the outer outlet than that for the inner outlet moved the 
streamline boundary closer to the outer outlet so that the flow for the inner outlet contained more focused cells 
than that for the outer outlet in the main channel (Supplementary Fig. S2), increasing the cell retention efficiency.
The cell retention efficiency in this microfluidic cell retention device also depends on the input cell concentra-
tion. Increased input cell concentrations result in increased cell-to-cell interaction because the cells compete with 
each other for the same equilibrium position along the channel. This led to broadening of the focused band and 
decreased efficiency of inertial focusing (Fig. 2c). The microfluidic device had 99.2% (0.1%) (mean (range), n = 3) 
cell retention efficiency for a cell concentration of 15.4 million cells/mL and 92.2% (0.8%) (mean (range), n = 3) 
cell retention efficiency for a cell concentration of 22.2 million cells/mL (Fig. 2c). However, the cell retention 
efficiency drops below 83% for the concentrations greater than 26.5 million cells/mL due to broadened focusing 
bands, resulting in cell loss to the outer outlet of the device. Still, the achieved level of cell retention was sufficient 
to enable long-term perfusion culture with >20 million cells/mL, with continuous cell bleeding (see below). The 
cell retention efficiency for the higher cell concentration such as 30–40 million cells/mL can be improved with the 
modified channel dimension and flow rates (Fig. 2d).
The cell retention devices need to be in a continuous operation, during long-term perfusion culture, without 
negatively affecting the cell growth and viability to maintain high cell concentrations in the bioreactor. The CHO 
cells at 4.2 million cells/mL (1.2 million cells/mL) (mean (range), n = 3) were continuously flowed through the 
cell retention device for more than 145 h, and processing of the cells through the retention device for a long-term 
Figure 1. The microfluidic cell retention device. (a) Cell retention by hollow fiber membranes and microfluidic 
cell retention device. (b) The schematic of the spiral microfluidic cell retention device. The channel size is 
26 mm × 26 mm with 8 loops and its volume is 28 μL. The width is 600 μm, and outer and inner depths are 
130 μm and 80 μm, respectively. 10.5 million/mL CHO cells occupied their equilibrium positions near the inner 
wall and went to the inner outlet. The cell-limited harvest stream flowed into the outer outlet. The two streams 
from outlets were collected in the tubes. The cell concentration of the harvest stream (outer outlet) had 0.3 
million cells/mL with the cell retention efficiency of 97%. Scale bar, 500 μm.
www.nature.com/scientificreports/
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Figure 2. Characterization of the spiral cell retention device in terms of cell retention efficiency, 
biocompatibility, and scalability. All error bars, data range (n = 3) (a) The cell retention efficiency can be 
maintained high at optimal flow rates. The cell culture at the average concentration of 4.8 million cells/mL was 
flowed into the inlet of the device, and the concentrations of the collected cell culture from the outlets were 
compared. The input flow rate of 1 mL/min had a cell retention efficiency of 99%. (b) Controlling fluid split 
at the outlets affects retention efficiencies. Decreasing the tubing diameter and increasing the tubing length 
increased the fluidic resistance of the outer outlet. The cell retention efficiency increased as the ratio of the 
fluidic resistance of the outer outlet to that of the inner outlet increased. Different ROO/RIO values of 4.5 (0.3), 2.7 
(0.3), and 1.5 (0.1) (mean (range), n = 3 each) were tested. (RIO: fluidic resistance of the inner outlet, ROO: fluidic 
resistance of the outer outlet). (c) The cell retention efficiency also depends on the input cell concentrations. The 
device had 91% cell retention efficiency for a cell concentration of 22.2 million cells/mL. (d) The cell retention 
device with a different dimension could improve cell retention capability. The width, inner depth, and outer 
depth of the channel were 1000 μm, 260 μm, and 80 μm, respectively. The cell retention efficiency was 84% for an 
input cell concentration of 43.6 million cells/mL. The input flow rate and fluidic resistance ratio were 4 mL/min  
and 1:0.1 (outer outlet:inner outlet), respectively. (e) The CHO cells (4.2 million cells/mL on average) were 
continuously processed by the single cell retention device with the average retention efficiency of 98% for 
>145 hours at the flow rate of 1 mL/min. The noticeable decrease in viability was not observed during three 
different runs. (f) Schematic diagram of scaled-out microfluidic cell retention technology and the cell retention 
performance of the five-layer stacked device. The four spiral channels are combined in one single layer, and the 
layers can be stacked to increase a perfusion rate.
www.nature.com/scientificreports/
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did not impact cell viability (Fig. 2e), while maintaining a cell retention efficiency of 98% (1.6%) (mean (range), 
n = 3). Moreover, the perfusion culture using the retention device maintained the same average specific growth 
rate (0.03 h−1) during exponential growth phase as that from batch cultures (See below for the perfusion cultures 
and Supplementary Table S2).
The throughput of the new cell retention technology needs to be high enough to process the large volumes 
(several thousand liters) from large-scale bioreactor tanks. The spiral inertial microchannels can be easily 
scaled-out using multiple devices in parallel (Fig. 2f). The five-layer stacked device showed cell retention perfor-
mance similar to that of a single-layer device (Fig. 2c and f). With the fluidic resistance ratio (inner outlet:outer 
outlet = 1:4) adjusted for the cell retention and the single input flow rate of 1 mL/min, the current single device 
can process the perfusion rate of 288 mL/day, and the four devices in parallel can handle the perfusion rate of 
1.15 L/day. With the modified design, the perfusion rate of a wider and deeper single chip can at least quadruple 
in that the input flow rates for cell sorting can be increased by four fold (Fig. 2d). As a demonstration of scalability 
of the cell retention technology, four spiral channels were combined in a single layer to perfuse 700 mL/day dur-
ing perfusion cultures (see below).
Perfusion culture using the spiral cell retention device. In this work three sequential perfusion cul-
tures of suspended CHO cells using the spiral cell retention device were carried out, as described in the Methods 
(Fig. 3). The IgG1-producing CHO cells were grown in a customized bioreactor with the working volume of 
350 mL. The cells were continuously flowed through the cell retention device using a peristaltic pump, and most 
of the cells (98.4% ± 1.1% (mean ± s.d., n = 15) in terms of total cell number) were recycled back to the bioreactor. 
The harvest solution containing IgG1 was collected from the outer outlet of the device. At the same time, fresh 
culture medium was supplied to the bioreactor to maintain a constant working volume.
The three separate bioreactor cultures were run for 18 to 25 days (Figs 3–5 and Supplementary Figs S3–S5). In 
the first bioreactor culture, the CHO cells were grown in a batch mode (no perfusion) for the first four days, fol-
lowed by the initiation of the perfusion culture at 2 VVD (vessel volume per day). The cell concentration reached 
22.7 million cells/mL by Day 10 and leveled off afterward (Fig. 4a), exceeding that from the batch cultures using 
the same cell line by four times (Supplementary Table S2). The peak cell concentration obtained was likely a result 
of limited nutrients and oxygenation (Fig. 4b and Supplementary Fig. S3), as well as increased “bleeding” of cells 
(reduced cell retention efficiency) at high cell concentration. Still, cell viability was maintained >97% after the per-
fusion began, and it was 99% ± 1% (mean ± s.d., n = 9) after the cell concentration peaked on Day 10 (Fig. 4a), con-
firming the long-term biocompatibility of the microfluidic cell retention device. The culture metabolic parameters 
such as glucose, lactate, glutamine, glutamate, and ammonium leveled off during the perfusion phase of the culture 
(Fig. 4b and Supplementary Fig. S3). The glucose concentration was stably maintained at 0.24 g/L after Day 10, 
creating a glucose-limited environment that was still able to support the high cell concentration in the bioreactor.
We compared the cell concentration in the bioreactor with that of the harvest stream (supernatant coming 
from the device outer outlet) on a daily basis (Fig. 4c). The cell retention efficiency was 99% ± 2% (mean ± s.d., 
n = 5) for cell concentrations <15 million cells/mL in the bioreactor. As the culture reached its peak concen-
tration of 20 to 23 million cells/mL, the average cell retention efficiency was 82% ± 3% (mean ± s.d., n = 10). 
The low cell number lost to the harvest bottle demonstrates that the cell retention through the spiral device was 
maintained throughout the culture (Fig. 4d). During this perfusion culture, the spiral cell retention device did not 
show any noticeable cell accumulation (Supplementary Fig. S4).
IgG1 production efficiency of the perfusion culture was also evaluated. The CHO cells in the bioreactor con-
tinuously produced recombinant IgG1, and the IgG1 concentration in the bioreactor increased with cell concen-
tration (Fig. 4e) and peaked at approximately 40 µg/mL after Day 9. The total harvest volume of 8.16 L during 
perfusion was collected, with a total IgG1 yield of 263 mg. The IgG1 production rate was 26.8 mg/day from Day 9.
The culture data demonstrated the feasibility for the use of the microfluidic cell retention device in mamma-
lian perfusion culture. Further studies are required to demonstrate the use of the device for large-scale perfusion.
Product recovery with the cell retention device. Since the spiral cell retention device does not have any 
micro- or nanoporous membrane, and the smallest channel dimension is in the order of ~100 µm, the recombi-
nant product generated from the cells can be directly collected without any retention or loss during perfusion 
cultures. To demonstrate high product recovery with the microfluidic device, another perfusion culture using the 
spiral cell retention device was performed for 18 days (Fig. 5a and Supplementary Fig. S5), and the IgG1 concen-
trations in the bioreactor and outer outlet of the device were measured. Both concentrations were similar during 




, where XI is 
the IgG1 concentration in the bioreactor (feed), and XOO is the IgG1 concentration in the harvest stream (perme-
ate). The IgG1 recovery efficiency was only 80% for the first two days, possibly due to adsorption of IgG1 to the 
tubing and fluidic adaptors, and then increased close to 100% thereafter (Fig. 5b).
Discussion
Other membrane-less cell retention technologies such as acoustic wave-based cell aggregation, centrifugation, and 
inclined sedimentation are available3, 4, 6, 8. Acoustic cell retention requires additional active components, such as high 
frequency (~2 MHz) ultrasonic transducers7. Centrifuges can create high shear stress on cells and have high operation 
and maintenance costs4, thus is not an ideal choice for continuous biomanufacturing. Inclined sedimentation has lim-
itations of long residence time of cells in the settler and low cell retention efficiency for high cell concentrations8. In 
contrast, our inertial sorting based microfluidic cell retention process is a simple, passive operation (no active field) with 
minimal maintenance needed (no filter/device replacement), and benign to cells with high cell viability demonstrated. 
Supplementary Table S3 shows a comparison among the spiral microfluidics and other cell retention technologies in 
terms of cell retention efficiencies, scalability, product recovery, dead cell removal, and capital and operation costs.
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Using the spiral cell retention device, we demonstrated perfusion cultures of the CHO cells with the concen-
tration of 20 to 30 million cells/mL using a commercial media formulation. With additional device optimization 
in terms of different device dimensions (e.g., large slant angle of the trapezoidal cross-section for increasing cell 
trapping capability38 and optimized bifurcated outlets), enabled by model-based engineering, the cell retention 
capability of the device can be further enhanced. Moreover, cascading multiple devices increases cell retention 
efficiency at high cell concentrations34, 39, 40. As the viscoelasticity of the cell culture rises with increasing cell 
concentration41, viscoelastic inertial microfluidics25–27, 42 will be useful to understand the focusing behavior of 
the high-concentration CHO cells and enhance the cell retention capability of the spiral cell retention devices. 
Furthermore, combination of other passive microfluidic cell separation technologies, such as vortex-assisted cell 
separation43–45, is worthwhile for future work. The aforementioned approaches may not be sufficient to process 
high cell concentration of >100 million cells/mL. However, whether the cell concentration during bioreactor 
cultivation should be increased to >100 million cells/mL remains unclear. This high cell concentration could 
result in issues, such as decreased mixing efficiency due to high medium viscosity, limited oxygenation, and 
high carbon dioxide accumulation46, 47, thus requiring sophisticated aeration and agitation strategies for reliable 
long-term biomanufacturing. Therefore, we believe that microfluidic cell retention below 100 million cells/mL is 
still meaningful.
Figure 3. The perfusion culture setup using the spiral microfluidic cell retention device. (a) The cell culture 
was continuously processed through the device by a peristaltic pump. The majority of the cells were recycled 
back to the bioreactor while the harvest was collected in a separate container. The cell culture medium was 
supplied to the bioreactor using another peristaltic pump. The working volume of the bioreactor was controlled 
automatically based on bioreactor weight using customized software. The pH and dissolved oxygen levels were 
monitored and controlled to meet established set points. (b) The microfluidic cell retention device and the 
fluidic adaptor. (c) The bottom view of the cell retention device. The four spiral channels were combined in 
parallel. Scale bar, 10 mm. (d) The pre-sterilized cell retention device, tubings, and bottles were connected to 
each other in a sterilized manner in the biosafety cabinet. (e) The setup was transferred into the standard CO2 
incubator, and the perfusion culture began after four days.
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Figure 4. The perfusion culture results. All error bars, data range (n = 3, technical replicates). (a) The 
bioreactor culture of the CHO cells was performed for 18 days. The perfusion began after the 4-day batch 
culture. The cells continued to proliferate until the cell concentration peaked at 22 million cells/mL. The leveled-
off concentration was 20 to 23 million cells/mL. The viability was maintained >98% after the cells became 
saturated. (b) The glucose and lactate levels were stabilized after the perfusion began. The stabilized glucose and 
lactate concentrations were 0.24 g/L and 2.46 g/L, respectively. No glucose spiking was done in this perfusion 
culture. The data points are average values from technical replicates (n = 2). (c) The cell concentrations of the 
bioreactor and the device outer outlet (permeate) were compared daily to measure cell retention efficiencies of 
the device. The cell retention device maintained the average cell retention efficiency of 82% for 20 to 23 million 
cells/mL throughout the perfusion culture. (d) The cell concentration (2.6 million cells/mL on average since 
Day 10) of the daily collected harvest bottles confirmed the continuous stable cell retention of the device. (e) 
The production of IgG1 was demonstrated in the perfusion culture.
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For large-scale perfusion culture (>100 L/day perfusion rate), the scale-out of the microfluidic cell retention 
devices using parallelization is required. Assuming a large spiral channel (1000 μm width, 260 μm inner depth, 
and 80 μm outer depth of the channel) with 4 mL/min input flow rate and 0.4 mL/min harvest flow rate at high cell 
concentrations (>40 million cells/mL), 1.7 channel is required for 1 L/day perfusion rate. For example, approx-
imately 600 channels are needed to process 1,000 L/day perfusion rate. The overall dimensions of this stacked 
device are 100 mm × 80 mm × 300 mm, assuming a single layer contains four spiral channels and is 2 mm thick. 
Enlarging channel dimensions while retaining cells under inertial microfluidics remains possible and can further 
reduce the number of spiral channels for decreased footprint. The stacked devices can also theoretically achieve 
uniform flow distribution because the common inlet and outlet paths (4 mm in diameter each) have significantly 
lower fluidic resistance than the dimensions of the spiral channel. Flow distribution in a 10-layered device was 
simulated, and uniform flow rates across each layer was demonstrated (Supplementary Fig. S6). The large number 
of the spiral channels (e.g., 600 channels for 1,000 L/day perfusion rate) is expected to contribute to stable cell 
retention during long-term cultures by minimizing the risk of the channel failure possibly due to large cell–cell 
debris aggregates. If one channel loses all cells to the harvest stream, the cell retention efficiency of the stacked 
device decreases by 1% but the fluid split ratio remains nearly the same, assuming the intact stacked device has 
90% cell retention and 9:1 (retentate:harvest) fluid split ratio.
At the high cell concentration (>20 million cells/mL) during perfusion using the conventional 
membrane-based filtration devices, 5 to 10% daily cell bleeds are commonly used to offset growth and maintain 
target cell densities at high cell viability, thereby achieving a steady state culture. The microfluidic cell reten-
tion device can also perform continuous cell bleeding at high cell density with no need for manual interven-
tion because a fraction of the cells can be removed from the bioreactor through the harvest flow (Fig. 4c,d and 
Supplementary Fig. S5). Moreover, the cell bleeding efficiency, as well as the target cell concentration, can be 
controlled via changing various parameters, such as input flow rate into the device, channel dimensions, and 
outlet fluidic resistance ratio (Fig. 2a–d). In addition, our spiral cell retention device based on inertial sorting can 
be configured to separate cells of different sizes with the specific input flow rates33, 38. Thus, the smaller non-viable 
cells with the cell debris could be continuously removed in the outflow, which provides a favorable culture envi-
ronment for cell growth and possible benefits to the culture (e.g., enhanced product quality23 and productivity22).
In the current study, we did not use a highly productive cell line or optimize the culture conditions to maxi-
mize mAb productivity. The mAb productivity of the CHO cells is known to be affected by many parameters, such 
as CO2 concentration in the bioreactor, culture temperature, and cell lines. Using our system, perfusion cultures 
with different culture parameters and cell lines could be performed to study the mAb productivity of the current 
CHO cell lines, at the lab scale (<0.5 L) perfusion culture volume. To the best of our knowledge, this work is the 
first demonstration of a benchtop scale (350 mL), high cell density, long-term perfusion culture using a microflu-
idic device, which can be applied to pharmaceutical process development and manufacturing.
Adjusting the fluidic resistance for the harvest stream using pinch or multiple-way valves enables the modulation 
of perfusion rates during cultivation. Kim and et al. demonstrated a long-term modulation of fluidic resistance using 
automated pinching/releasing mechanism48. In addition, multiple-way valves can be connected to the harvest stream 
so that users can choose different fluidic paths with varied fluidic resistances. If the modulation of fluidic resistance 
ratio at the outlets significantly affects cell retention efficiency, then users can increase the number of spiral chips to 
process the target perfusion rates while maintaining the fluidic resistance ratio for each spiral channel.
Figure 5. Antibody recovery by the microfluidic cell retention device. (a) Antibody concentrations from the 
bioreactor and outer outlet (the permeate stream) of the device were compared daily. Error bars, data range 
(n = 3, technical replicates). (b) The recovery efficiency close to 100% demonstrates that the microfluidic cell 
retention device does not suffer from the low product recovery, compared with the membrane-based filtration 
technologies.
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Also, the spiral cell retention device tested here was made of polydimethylsiloxane, a low-cost platinum-cured 
silicone commonly used in pharmaceutical and bioprocessing industries49, 50. The dimensions of the microfluidic 
channels (~100 µm) are well within the limit of standard plastics manufacturing processes (i.e., injection molding 
using polystyrene), with the possibility of significantly lowering the unit cost.
As the membrane-less microfiltration based on inertial sorting is applicable to other microorganisms such 
as yeast and bacteria33, interesting applications such as production of biofuels and biochemicals using smaller 
microorganisms51 could be also contemplated.
Lastly, it is expected that membrane-less microfiltration based on inertial microfluidics will find many other 
industrial applications by separating large scale suspension efficiently and at lower cost than conventional 
membranes35.
Methods
Fabrication of cell retention devices. Microfluidic channels were fabricated using standard soft lithog-
raphy. The molds for microfluidic channels were designed using a 3D modeling tool (Rhinoceros, McNeel North 
America, USA). The single spiral channel (600 μm width, 80 μm inner depth, and 130 μm outer depth) possessed 
eight loops and an outlet width of 300 μm. The four spiral channels in parallel possessed six loops and an enlarged 
width (520 μm) for the inner outlet. The aluminum channel molds were fabricated using micromachining (Whits 
Technologies, Singapore). Polydimethylsiloxane (PDMS) elastomer (Sylgard® 184, Dow Corning, USA) was pre-
pared and the solution was poured into the aluminum molds and cured at 150 °C for 15 min on a hotplate. The 
solidified patterned PDMS slab was removed from the mold and punched with a 4 mm puncher to make inlets 
and outlets. The slab was bonded to a flat glass slide (260230, Ted Pella, USA) or thin PDMS layer (<500 um) 
using oxygen plasma treatment (Harrick Plasma Cleaner, Harrick Plasma, USA). The assembled PDMS micro-
channel was cured at 95 °C overnight on a hotplate. Silicone tubings (Masterflex, Cole-Parmer, USA) for fluid 
transfer were inserted into inlets and outlets of the microchannel the next day. Finally, the glass or acrylic slide 
with drilled holes was placed on top of the microchannel, and they were clamped with binder clips for long-term 
robust operation.
Cell batch culture. CHO-DG44 cells producing human IgG1 against CD40 ligand were gifted from Biogen 
Idec, MA, USA. Commercial culture medium (12681011, CD OptiCHOTM, Thermo Fisher Scientific, USA) 
was used with 50 µM of L-methionine sulfoximine (M5379, Sigma-Aldrich, USA). Suspension cultures were 
performed in an autoclaved spinner flask (4500-500, PYREX ProCulture Spinner Flask, Corning, USA) on a 
magnetic stirrer. Cell concentrations, viabilities, live cell diameters, pH values, gases, electrolytes, nutrients, and 
metabolites were measured by the automated analyzer (BioProfile FLEX and CDV Analyzers, Nova Biomedical, 
USA). The cells from a sample cell culture are spread in a single layer in a chamber, and live cells are marked by 
trypan blue dye exclusion. For each measurement, 40 images are obtained from 40 different fields of view. Their 
diameter is determined by measuring a pixel distance, and the cell concentration is measured by counting cells 
in images. For example, 6,000 and 12,000 CHO cells are captured to obtain total cell concentrations of 5 and 10 
million cells/mL, respectively.
Device characterization. Several tubes (Falcon Centrifuge Tube, Corning, USA) of the cells were com-
bined after centrifugation to create high cell concentrations (>8 million cells/mL). The cell retention device was 
mounted on an inverted microscope (IX51, Olympus, USA), and cells were loaded into a syringe (BD Luer-LokTM 
tip syringe, Becton, Dickinson and Company, USA). Subsequently, a syringe pump delivered the cell solution 
to the device. The focusing behavior of CHO cells in the microfluidic cell retention device was captured by a 
high-speed camera (Phantom V9.1, Vision Research, USA). To measure the cell retention efficiency, three sets 
of both inner and outlet samples in tubes were obtained sequentially per experimental condition. Afterward, the 
cells collected from both outlets were analyzed by the automated equipment (Bioprofile CDV Analyzer, Nova 
Biomedical, USA) to obtain cell concentration and viability. The maximum deviation from mean concentra-
tion was 4.8% ± 3.7% (mean ± s.d., n = 32) for cell concentration of >1 million cells/mL. Input cell concentra-
tions were estimated using volume ratios and average cell concentrations of outlet samples. The fluidic resistance 
ratio at the outlets was modified by attaching a small-diameter (inner diameter, 510 µm) tubing (EW-06420-02, 
Cole-Parmer, USA) and adjusting its length. A resistance ratio was calculated as the ratio of the weight of solu-
tions collected from each outlet. For long-term viability measurement, the cell culture in a spinner flask with a 
working volume of 250 mL was continuously recycled through the cell retention device at a flow rate of 1 mL/min. 
The cell culture in the flask was perfused with a fresh culture medium at 0.2 mL/min, and the working volume 
was maintained without pH and dissolved oxygen (DO) controls. The daily cell culture sample was aliquoted 
into three vials, and concentration and viability were measured by the automated equipment (Bioprofile CDV 
Analyzer, Nova Biomedical, USA).
Perfusion culture. A spinner flask was customized for DO and pH controls. The flask with pH/DO probes 
and tubings was sterilized using autoclave. The setup was connected in a biosafety cabinet to the presterilized 
glass bottles (culture medium, base solution, cell inoculation, and harvest collection). The microfluidic retention 
device was sterilized by flushing the channel with 10% bleach and 70% ethanol for at least 10 min using a peristal-
tic pump (07522-20, Masterflex, USA). Subsequently, the device was connected to the sidearm ports of the flask 
and harvest bottle. Afterward, 400 mL of the prewarmed sterilized culture medium was transferred into the flask. 
Finally, the whole setup, except for the base solution and harvest bottles, was moved into standard CO2 incubators 
to maintain the stable temperature at 37 °C. The flask was placed on a magnetic stirrer (440811, Corning, USA), 
and the stirring revolution per minute (RPM) was 45 throughout the culture. Bioreactor controllers (BioFlo/
CelliGen 115 systems, New Brunswick Scientific, USA; BIOSTAT A bioreactor controller, Sartorious, USA) were 
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used to control pH (7.0) and DO (40%, with respect to air saturation). The CHO cells were inoculated by a per-
istaltic pump from the inoculation bottle to the spinner flask. The initial cell concentration was 0.3–0.4 million 
cells/mL, and the cells were grown in a batch mode prior to perfusion. During perfusion of culture, fresh culture 
medium and cell broth were fed in the spinner flask and the microfluidic retention device, respectively, by using 
two peristaltic pumps (07522-20, Masterflex, USA; 120U/DV, Watson Marlow, USA). The working volume of the 
culture was maintained at approximately 350 mL throughout the perfusion of culture using a customized control 
system. The harvest bottle was replaced daily during perfusion. Cell concentration was measured from technical 
replicates (three aliquots). The maximum deviation from mean concentration was 3.8% ± 2.9% (mean ± s.d., 
n = 64) for cell concentration of >1 million cells/mL.
Antibody concentration measurement. The supernatant antibody concentrations were determined 
by performing a high-performance liquid chromatographic assay using an affinity chromatography column 
(2-1001-00, Applied Biosystems, USA) on a liquid chromatography system (1100 Series, Agilent, USA). An 
equilibration/wash buffer of pH 7 contained 50 mM phosphate (Sigma-Aldrich, USA) and 150 mM sodium 
chloride (Sigma-Aldrich, USA). An elution buffer of pH 2.5 contained 100 mM phosphate and 0.4% (v/v) of 
phosphoric acid (85 wt%, Sigma-Aldrich, USA). The purified IgG1, Kappa from human myeloma plasma (I5154, 
Sigma-Aldrich, USA) was used to generate a reference standard curve.
Data availability. All the raw data were stored in a laboratory server and concurrently backed up to remote 
locations. The data will be made available in response to any reasonable requests, after the publication and com-
pletion of necessary intellectual property-related steps.
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